Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents
- PMID: 22472987
- DOI: 10.1038/clpt.2012.12
Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents
Abstract
Major advances in the field of carrier-mediated agents (CMAs) have revolutionized drug delivery capabilities over the past decade. While providing numerous advantages over their small-molecule counterparts (solubility,duration of exposure, and delivery to the site of action are higher), these agents display substantial variability in systemic clearance (CL) and distribution, tumor delivery, and pharmacologic effects. This review provides an overview of factors that affect the pharmacokinetics (PK) and pharmacodynamics (PD) of CMAs in preclinical models and patients.
Similar articles
-
The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.Nanomedicine (Lond). 2015 Feb;10(3):447-63. doi: 10.2217/nnm.14.179. Nanomedicine (Lond). 2015. PMID: 25707978 Free PMC article. Review.
-
Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.Expert Opin Drug Metab Toxicol. 2015;11(9):1419-33. doi: 10.1517/17425255.2015.1057496. Epub 2015 Jul 20. Expert Opin Drug Metab Toxicol. 2015. PMID: 26173794 Review.
-
Clinical pharmacokinetics and pharmacodynamics of anticancer agents in pediatric patients (review).Anticancer Res. 1993 Sep-Oct;13(5C):1795-808. Anticancer Res. 1993. PMID: 8267385 Review.
-
Concept and clinical evaluation of carrier-mediated anticancer agents.Oncologist. 2008 Mar;13(3):248-60. doi: 10.1634/theoncologist.2007-0180. Oncologist. 2008. PMID: 18378535 Review.
-
Methods and Study Designs for Characterizing the Pharmacokinetics and Pharmacodynamics of Carrier-Mediated Agents.Methods Mol Biol. 2018;1831:201-228. doi: 10.1007/978-1-4939-8661-3_15. Methods Mol Biol. 2018. PMID: 30051434
Cited by
-
Functional-segregated coumarin-containing telodendrimer nanocarriers for efficient delivery of SN-38 for colon cancer treatment.Acta Biomater. 2015 Jul;21:85-98. doi: 10.1016/j.actbio.2015.04.021. Epub 2015 Apr 22. Acta Biomater. 2015. PMID: 25910639 Free PMC article.
-
The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.Nanomedicine (Lond). 2015 Feb;10(3):447-63. doi: 10.2217/nnm.14.179. Nanomedicine (Lond). 2015. PMID: 25707978 Free PMC article. Review.
-
Unintended effects of drug carriers: Big issues of small particles.Adv Drug Deliv Rev. 2018 May;130:90-112. doi: 10.1016/j.addr.2018.06.023. Epub 2018 Jul 3. Adv Drug Deliv Rev. 2018. PMID: 30149885 Free PMC article. Review.
-
Macrophage silica nanoparticle response is phenotypically dependent.Biomaterials. 2015;53:574-82. doi: 10.1016/j.biomaterials.2015.02.070. Epub 2015 Mar 23. Biomaterials. 2015. PMID: 25890753 Free PMC article.
-
Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems.Pharmaceutics. 2021 Jan 17;13(1):114. doi: 10.3390/pharmaceutics13010114. Pharmaceutics. 2021. PMID: 33477395 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous